相关实验视频

Updated: Jun 12, 2025

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease

Published on: October 13, 2016

德国目前诊断阿尔茨海默病的能力以及对等待时间的影响

Soeren Mattke¹, Yu Tang¹, Mark Hanson¹

¹The USC Brain Health Observatory, USC Dornsife, Los Angeles, CA, USA.

Journal of Alzheimer's disease : JAD

|September 20, 2024

概括

德国德国德国德国

科学领域:

神经学神经学
医疗保健服务研究医疗服务研究
药物经济学药物经济学

背景情况:

针对阿尔茨海默病 (AD) 的粉样蛋白向疗法在德国已经接近可用性.
德国的医疗保健系统在诊断符合新的AD治疗条件的患者方面面临挑战,原因是患病率高和复杂的诊断.
及时和公平的患者鉴定对于有效的AD治疗实施至关重要.

研究的目的:

评估德国医疗保健系统在识别阿尔茨海默病 (AD) 患者的能力,这些患者有资格接受粉样蛋白向治疗.
预测诊断和治疗启动的潜在等待时间.
评估诊断策略对医疗保健系统能力和患者获取机会的影响.

主要方法:

开发了一个模拟模型来分析阿尔茨海默病 (AD) 患者的诊断旅程.
预计AD专家访问和PET扫描的预期等待时间从2024年到2043年计算出来.
模型参数由已公布的数据和专家共识提供信息.

主要成果:

如果没有干预,阿尔茨海默病 (AD) 诊断的等待时间可能达到大约50个月.
与私人医疗保险患者相比,社会医疗保险患者的等待时间 (1.9倍) 显着更长.
实施AD血液测试作为初级保健分拣步骤可以将等待时间缩短到24个月以下.

结论:

德国资源充足的医疗保健系统可能很难满足对基于生物标志物的阿尔茨海默病 (AD) 诊断的需求.
紧急实施包括血液检测在内的AD诊断策略是必要的,以确保及时和公平地获得新疗法.
如果不采取行动,可能会导致治疗延迟,并加剧阿尔茨海默病 (AD) 护理中的健康不平等.

关键词:

阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.生物标志物生物标志物诊断诊断诊断诊断诊断诊断改变疾病的治疗方法.卫生系统的准备卫生系统的准备专门的护理专业的护理.等待次数乘以等待次数

更多相关视频

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on ¹⁸F-AV-1451

Published on: April 18, 2025

相关概念视频

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

Dementia

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...